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1446Allogeneic Hematopoietic Cell Transplantation for
Advanced Polycythemia Vera and Essential
Thrombocythemia
Karen K. Ballen,1 Ann E. Woolfrey,2 Xiaochun Zhu,3 Kwang Woo Ahn,4 Baldeep Wirk,5
Mukta Arora,6 Biju George,7 Bipin N. Savani,8 Brian Bolwell,9 David L. Porter,10 Ed Copelan,9
Gregory Hale,11 Harry C. Schouten,12 Ian Lewis,13 Jean Yves Cahn,14 Joerg Halter,15
Jorge Cortes,16 Matt E. Kalaycio,9 Joseph Antin,17 Mahmoud D. Aljurf,18
Matthew H. Carabasi,19 Mehdi Hamadani,20 Philip McCarthy,21 Steven Pavletic,22
Vikas Gupta,23 H. Joachim Deeg,2 Richard T. Maziarz,24 Mary M. Horowitz,3 Wael Saber3Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential
thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years)
and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer
Research Center (FHCRC; n5 43) or at other Center for International Blood andMarrow Transplant Research
(CIBMTR) centers (n 5 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splen
ectomy. Most patients (69% for ETand 67% for PV) received a myeloablative (MA) conditioning regimen. Cumu-
lative incidenceof neutrophil engraftment at 28 dayswas 88% for ETpatients and 90% for PV patients. Acute graft-
versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ETand PV patients, respectively. The
1-year treatment-related mortality (TRM) was 27% for ETand 22% for PV. The 5-year cumulative incidence of
relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and
71%/48% forETandPV, respectively. Patientswithout splenomegalyhad fasterneutrophil andplatelet engraftment,
but therewere no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment
or TRM. Over 45% of the patients who undergo transplantations for ETand PVexperience long-term PFS.
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Polycythemia vera (PV) and essential thrombocy-
themia (ET) are Philadelphia chromosome-negative
myeloproliferative neoplasms with long natural histo-
ries. PV is characterized by elevated red blood cell
mass, often accompanied by high platelet count and
WBC counts and splenomegaly. ET is characterized
almost exclusively by a high platelet count. Both dis-
eases may evolve to myelofibrosis (MF), or can poten-
tially transform to acute myeloid leukemia (AML).
Both diseases have been linked to the acquired muta-
tion V617F in the Janus kinase 2 (JAK2) gene [1,2].
Almost all patients with PV and one-half of those
with ET have a JAK2 mutation involving either exon
12 or 14 [3]. The diagnostic criterion for PV and ET
have been revised to include these molecular findings,
and clinical trials with oral inhibitors of the JAK2 ki-
nase are under way [3]. Patients with ET are at in-
creased risk of both thrombosis and bleeding. The
incidence of thrombosis ranges from 6% to 10% per
patient-year and the incidence of bleeding from 1%
to 3% per patient-year [4]. The risk of evolution to
MF or AML is approximately 2% and 4%, respectively
[5-7]. Most patients with low-risk ET do well on low-
dose aspirin alone, whereas hydroxyurea, anagrelide,
and interferon are used for cytoreduction in some
high-risk patients [8,9]. However, the rate of
thrombotic events remains at 1.7% per patient year,
which can contribute to significant morbidity [10].
Patients with PV are at higher risk of thrombosis,
often in large vessels [11]. The risk of progression to
MF is estimated at 5% to 15% [11]. An analysis of
1638 patients with PV revealed 22 cases of myelodys-
plastic syndrome (MDS)/AML, occurring at a median
of 8 years from diagnosis [12]. All cases were fatal
within 6 months. Advanced age, higher WBC at diag-
nosis, and prior treatment with alkylating agents in-
creased the risk of MDS/AML. Other studies of
patients with PV have reported an incidence of AML
approaching 15% [13]. A recent report indicated that
25% of patients with myeloproliferative neoplasms
who developed MDS/AML were never exposed to al-
kylating agents, highlighting the fact that this compli-
cation is part of the natural history of the disease [14].
Allogeneic hematopoietic cell transplantation (HCT)
is not typically considered until late in the course of
these disorders or when the disease cannot be con-
trolled with conventional therapies.
Although PV and ET are usually indolent diseases,
HCT may be a therapeutic option particularly for
patients with high-risk features such as recurrent
thrombosis or rapid or difficult to control disease
progression [13]. If HCT is to be performed, ideal
timing would be before transformation to AML.
There is a paucity of data describing post-HCT
outcomes in these diseases, and only small studieswere previously reported [15,16]. In this study, the
largest report dedicated to PV and ET, we analyze
the long-term outcomes of 117 patients with PV and
ET undergoing allogeneic HCT, generally at ad-
vanced stages of their disease, and describe the effect
of prognostic factors, such as spleen status and MF,
on transplantation outcomes.MATERIALS AND METHODS
Data Source
The Center for International Blood and Marrow
TransplantResearch (CIBMTR) is a combined research
program of the Medical College of Wisconsin and the
National Marrow Donor Program. CIBMTR com-
prises a voluntary network of more than 450 transplan-
tation centers worldwide that contribute detailed data
onconsecutiveallogeneicandautologousHCTtoacen-
tralized Statistical Center. Observational studies con-
ducted by the CIBMTR are performed in compliance
with all applicable federal regulations pertaining to the
protection of human research participants. Protected
Health Information used in the performance of such
research is collected and maintained in CIBMTR’s ca-
pacity as aPublicHealthAuthority under theHealth In-
surance Portability and Accountability Act Privacy
Rule. Additional details regarding the data source have
been described elsewhere [17].
Patients treated at the Fred Hutchinson Cancer
Research Center (FHCRC), a CIBMTR-affiliated
center, gave informed consent for the transplantations
and for the use of medical information for research.
This retrospective study was approved by the Institu-
tional Review Board of the FHCRC.Patients
The study included all consecutive patients who
received related or unrelated allogeneic HCT with
bone marrow or peripheral blood cells for PV or ET
between 1990 and 2007 and were treated at the
FHCRC or reported to the CIBMTR research data-
base. Patients receiving high-intensity myeloablative
(MA), low- or reduced-intensity conditioning (RIC),
or nonmyeloablative (NMA) transplantations were in-
cluded. Patients whose disease had transformed to MF
or MDS were included. Patients who received synge-
neic or umbilical cord blood transplants or whose dis-
ease had progressed to AML were excluded.
The final study cohort consisted of 117 patients.
The follow-up completeness index from time of
HCT, which is the ratio of total observed person-time
to the potential person-time of follow-up in a study,
was 95% at 1 year after HCT, 91% at 2 years, and
84% at 3 years [18].
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The primary endpoint of this study was to deter-
mine the survival in patients with PV and ET who un-
derwent HCT. Patients were considered to have an
event at time of death from any cause; survivors were
censored at last contact. Secondary endpoints included
progression-free survival (PFS), recurrent/progressive
disease, treatment-related mortality (TRM), engraft-
ment, and graft-versus-host disease (GVHD). TRM
was defined as death occurring in remission, or with
stable disease; recurrence/progression was considered
a competing event. Recurrent disease/disease progres-
sion was defined as time to first evidence of recurrence
or progression of disease as reported to the CIBMTR
by the transplantation centers, and TRM was consid-
ered a competing event. PFS was defined as survival
without progressive or recurrent disease. Recurrent
disease/disease progression and death in remission
were considered events. For recurrence/progression,
TRM, and PFS, patients alive in continuous remission
or had a stable disease (as reported to the CIBMTR by
the transplantation centers) were censored at last
follow-up. Transplantation centers were asked to pro-
vide data on disease recurrence/progression on stan-
dard follow-up forms. Transplantation centers
defined relapsed/progressive disease according to their
own criteria, as there were no established criteria for
relapsed disease at this time.
Secondary endpoints included neutrophil recov-
ery, defined as time to an absolute neutrophil count
.0.5  109/L sustained for 3 consecutive days, and
platelet recovery, defined as time to achieve a platelet
count of .20  109/L without platelet transfusions
for 3 consecutive days. The diagnosis of acute
GVHD (aGVHD) was based on the occurrence of
grades II, III, or IV skin, gastrointestinal, or liver ab-
normalities according to the Glucksberg-Seattle crite-
ria of aGVHD [19]; and chronic GVHD (cGVHD)
was based on the occurrence of symptoms in any organ
system fulfilling the criteria for cGVHD [20]. For en-
graftment and GVHD, death without the event was
considered a competing event. All outcomes were as-
sessed from the date of HCT. Preparative regimens
were classified as high or lower intensity. High-inten-
sity regimens included those fulfilling the CIBMTR
Regimen-Related Toxicity Working Committee’s
published criteria for MA regimens; lower-intensity
regimens included those fulfilling the criteria for re-
duced-intensity or NMA conditioning [21].Statistical Analysis
Patient, disease, and treatment-related factors were
analyzed using chi-square test for categorical and
Kruskal-Wallis test for continuous variables. TRM,
recurrence/progression, engraftment, aGVHD, and
cGVHD were estimated as cumulative incidents,taking into account competing risks. Survival and
PFS were calculated using the Kaplan-Meier product
limit estimate [22].
Due to small patient numbers, multivariate analy-
sis was not performed. Univariate analysis of the asso-
ciation between survival and the following a priori
proposed prognostic factors was conducted: disease
(ET versus PV), age, presence of MF, spleen status
(splenectomy versus splenomegaly versus normal
spleen), time from diagnosis to transplantation, blood
counts at HCT, presence of circulating blasts in pe-
ripheral blood at HCT, donor–recipient HLA match-
ing, center, and conditioning regimen. For continuous
variables (age, time from diagnosis to HCT, and blood
counts at HCT), the median value was identified and
the cohort divided into those with values greater or
smaller than the median. Survival curves were com-
pared using the log-rank test. Probabilities of survival
were also compared at 1, 3, and 5 years using a point-
wise test.
Univariate analysis of the association between con-
ditioning regimen intensity and TRM was also con-
ducted. The association between GVHD (cGVHD/
aGVHD) and relapse/progression was examined in
a proportional hazards model by adding GVHD as
a time dependent covariate. SAS software, version
9.1 (SAS Institute, Cary, NC) was used in all analyses.RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1.
Our cohort included 75 patients with ET and 42 pa-
tients with PV. The median age at transplantation
was 50 years. Over 90% of patients were white. The
median interval from diagnosis to HCT was 94
months. Patients treated at the FHCRC were younger
and had longer time from diagnosis to HCT (140
months for the FHCRC patients versus 81 months
for the non-FHCRC patients; P 5 .002). MA condi-
tioning regimens were given to 68% of patients. Pe-
ripheral blood stem cells were used as the stem cell
source in 68% of patients. About one-third of the pa-
tients received organs that were transplanted from an
HLA-identical sibling. The remaining two-thirds re-
ceived the transplant from unrelated donors; among
these patients, 70% received the transplant from
a well-matched unrelated donor. Median follow-up
of surviving patients was 51 months. Data on JAK2
mutation status, thromboembolic events, or the devel-
opment ofMDS before HCTwere not available in this
cohort that dates back to 1990. Cytogenetic data were
available on 43% of the patients, and most had a nor-
mal karyotype. Patients received a variety of treat-
ments before HCT including steroids, interferon,
and low-dose chemotherapy. The reasons for
Table 1. Characteristics of Patients Receiving Allogeneic
Transplants for ETand PV, Reported to the CIBMTR between
1990 and 2007
Characteristics of Patients ET PV
Patient related
Number of patients 75 42
Number of centers 32 23
Patient age, median
(range), years
49 (20-64) 53 (30-66)
21-40 18 (24) 3 (7)
41-50 22 (29) 16 (38)
51-60 29 (39) 16 (38)
>60 6 (8) 7 (17)
Sex
Male 29 (39) 23 (55)
Race group
White 72 (96) 38 (90)
Black 0 1 (2)
Asian/Pacific Islander 1 (1) 1 (2)
Other 1 (1) 2 (5)
Missing 1 (1) 0
Karnofsky score before
transplantation
<90% 29 (39) 15 (36)
$90% 41 (55) 25 (60)
Missing 5 (7) 2 (5)
Spleen status at
transplantation
Normal spleen 27 (36) 7 (17)
Splenomegaly 28 (37) 16 (38)
Splenectomy 16 (21) 17 (40)
Missing 4 (5) 2 (5)
WBC at time of transplantation,
median (range), 109/L
8 (1-67) 15 (2-97)
Platelet count at time of
transplantation, median
(range), 109/L
322 (11-2000) 265 (32-2000)
Hemoglobin at time of
transplantation, median
(range), g/dL
11 (7-16) 12 (7-16)
Blast % in blood at time of
transplantation, median
(range)
0 (<1-11) 0 (<1-6)
Transformation to MF
Absent 39 (52) 21 (50)
Present 29 (39) 17 (40)
Unknown 7 (9) 4 (10)
Transplant related
Diagnosis to transplantation,
median (range), months
91 (4-317) 120 (8-326)
TBI given as part of conditioning 20 (27) 10 (24)
Conditioning regimen intensity
and regimen
MA 52 (69) 28 (67)
Cyclophosphamide + TBI 14 (27) 5 (18)
Busulfan +
cyclophosphamide
31 (60) 18 (64)
Busulfan +/2 other 6 (12) 3 (11)
TBI +/2 other 1 (2) 2 (7)
NMA 23 (31) 14 (33)
Busulfan +
Cyclophosphamide
2 (9) 1 (7)
TBI +/2 other 5 (22) 3 (21)
Busulfan +/2 other 11 (48) 7 (50)
Fludara + melphalan +/2
other
5 (22) 3 (21)
Donor type
HLA-identical sibling 19 (25) 13 (31)
Well matched, unrelated* 41 (55) 21 (50)
Partially matched, unrelated† 15 (20) 8 (19)
Donor–recipient sex match
(Continued )
Table 1. (Continued )
Characteristics of Patients ET PV
M–M 20 (27) 13 (31)
F–F 25 (33) 9 (21)
M–F 17 (23) 8 (19)
F–M 13 (17) 12 (29)
Donor/recipient CMV status
D(+)/R(+) 21 (28) 17 (40)
D(+)/R(2) 5 (7) 3 (7)
D(2)/R(+) 14 (19) 7 (17)
D(2)/R(2) 30 (40) 13 (31)
Missing 5 (7) 2 (5)
Graft type
Bone marrow 23 (31) 14 (33)
Peripheral blood 52 (69) 28 (67)
Year of transplantation
1990-1995 8 (11) 5 (12)
1996-2000 15 (20) 6 (14)
2001-2005 33 (44) 19 (45)
2006-2007 19 (25) 12 (29)
GVHD prophylaxis
Tacrolimus + methotrexate 39 (52) 23 (55)
Cyclosporine + methotrexate 31 (41) 17 (40)
Others 5 (7) 2 (5)
Median follow-up of survivors
(range) months
51 (11-169) 52 (3-154)
ET indicates essential thrombocythemia; PV, polycythemia vera;
CIBMTR, Center for International Blood and Marrow Transplant Re-
search; TBI, total body irradiation; MA, myeloablative; NMA, nonmye-
loablative; CMV, cytomegalovirus; GVHD, graft-versus-host disease.
*Well-matched unrelated includes: 8/8 or 6/6 allele matched.
†Partially matched unrelated includes: (1) Single allele mismatch 7/8; (2)
Single antigen mismatch 7/8; (3) 8/8 antigen matched at HLA-A, HLA-B,
HLA-C, and HLA-DRB1 (allele level typing not available on all loci).
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sistently. Thirty-nine percent of patients had trans-
formed to MF by the time of HCT.
Table 2 describes outcomes separately for patients
with ET and PV. In the entire cohort (ET and PV pa-
tients as 1 group), the median time to neutrophil en-
graftment was 16 days (range, 1-398 days). The
incidence of primary graft failure (no neutrophil en-
graftment by day 28) was 11%. One patient with graft
failure showed autologous recovery and lived to day
1735. The median time to platelet engraftment was
20 days (range, 1-126 days). At 100 days, the incidence
of aGVHD grades II to IV was 54%. The incidence of
cGVHD at 5 years was 48%. The incidence of TRM
was 16% at 100 days, 25% at 1 year, and 33% at 5
years.
Relapse and Survival
In the entire cohort, the 1-year and 5-year risk of
relapse/progression was 16% and 19%, respectively
(Table 2). The 1-year and 5-year survival for ET was
69% and 55%, respectively, and for PV it was 71%
and 71%, respectively (Table 2 and Figure 1). The re-
spective figures for PFS were 62% and 47% for ET
and 54% and 48% for PV (Table 2 and Figure 2).
For ET, the median follow-up of patients was 51
Table 2. Univariate Analysis of Post-HCTOutcomes for Advanced ETand PV
Characteristics ET Probability (95% CI) PV Probability (95% CI)
Neutrophil engraftment median (range) 16 (1-53) 17 (1-398)
Platelet engraftment median (range) 19 (1-126) 21 (1-79)
Outcomes
Neutrophil engraftment n 5 74 n 5 40
at 28 days 88 (80-94) 90 (79-97)
at 100 days 95 (89-98) 95 (87-99)
Platelet engraftment n 5 75 n 5 40
at 28 days 59 (47-69) 65 (50-79)
at 100 days 80 (70-88) 80 (66-91)
aGVHD grade II-IV n 5 75 n 5 42
at 100 days 57 (45-68) 50 (35-65)
aGVHD grade III-IV n 5 75 n 5 42
at 100 days 21 (13-31) 24 (12-38)
cGVHD n 5 72 n 5 39
at 1 year 40 (29-51) 52 (35-68)
at 5 years 47 (35-59) 52 (35-68)
Treatment-related mortality n 5 75 n 5 42
at 100 days 16 (9-25) 17 (7-29)
at 1 year 27 (18-38) 22 (11-36)
at 5 years* 40 (28-53) 22 (11-36)
Progression/relapse n 5 75 n 5 42
at 1 year 11 (5-19) 25 (13-39)
at 5 years* 13 (6-21) 30 (17-45)
Progression-free survival
NEval n 5 75 n 5 42
at 1 year 62 (51-73) 54 (38-69)
at 5 years 47 (35-60) 48 (33-63)
Survival
NEval n 5 75 n 5 42
at 1 year 69 (58-79) 71 (56-84)
at 5 years 55 (42-67) 71 (56-84)
HCT indicates hematopoietic cell transplantation; ET, essential thrombocythemia; PV, polycythemia vera; CI, confidence interval; aGVHD, acute graft-
versus-host disease; cGVHD, chronic graft-versus-host disease; NEval, number evaluable.
*Pointwise P < .05.
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patients were at risk. At 169 months, 14 of the 15 at-
risk patients were still alive, and of those, 13 were
disease-free. For PV, the median follow-up was 52
months with a maximum of 154 months. At 5 years,
11 patients were at risk. At 154 months, 10 of the 11
at-risk patients were still alive, and of those, 7 were dis-
ease-free.Figure 1. Overall survival of patients with essential thrombocythemia
(ET) and polycythemia vera (PV) undergoing allogeneic hematopoietic
cell transplantation (HCT).Causes of Death
Death occurred in 42% of patients with ET and
31% of patients with PV. The causes of death after
HCT are listed in Table 3. The most common re-
ported causes of death for patients with ETwere organ
toxicity (50%) and GVHD (22%). Organ toxicity in-
cluded death from pneumonitis, adult respiratory dis-
tress syndrome, and organ failure. The most commonFigure 2. Progression-free survival of patients with essential thrombo-
cythemia (ET) and polycythemia vera (PV) undergoing allogeneic hema-
topoietic cell transplantation (HCT).
Table 3. Primary Cause of Death
Cause of Death ET PV
Total number of deaths 32 13
Infection 6 (19) 2 (15)
GVHD 7 (22) 2 (15)
Primary disease 1 (3) 3 (23)
Organ toxicity 16 (50) 5 (38)
Secondary malignancy 2 (6) 1 (8)
ET indicates essential thrombocythemia; PV, polycythemia vera; GVHD,
graft-versus-host disease.
Table 4. Univariate Analysis of Risk Factors of Survival
Overall Survival
Probability
(95% CI)
at 1 Year
Probability
(95% CI)
at 5 Years
Patient age at transplantation
<50 years (median, n 5 55) 69 (56-80) 61 (47-74)
$50 years (median, n 5 62) 71 (59-82) 61 (48-73)
WBC at transplantation
<9.7  109/L (median, n 5 57) 68 (55-79) 59 (46-72)
$9.7  109/L (median, n 5 58) 72 (60-83) 62 (48-76)
Platelet count at transplantation
<307109/L (median, n 5 55) 65 (52-77) 57 (42-71)
$307109/L (median, n 5 56) 77 (65-87) 68 (54-80)
Hemoglobin at transplantation
<11 g/dL (median, n 5 42) 67 (52-80) 59 (42-75)
$11 g/dL (median, n 5 58) 76 (64-86) 67 (54-79)
Circulating blasts in peripheral
blood at transplantation
No blast (n 5 60) 65 (52-76) 55 (41-68)
Blast (n 5 27) 62 (43-79) 48 (26-71)
Graft source
Bone marrow (n 5 37) 62 (46-77) 59 (43-74)
Peripheral blood (n 5 80) 73 (63-83) 60 (48-73)
Time from diagnosis to transplantation
<95 months (median, n 5 58) 64 (51-76) 58 (45-70)
$95 months (median, n 5 57) 75 (63-85) 63 (49-76)
Donor–recipient HLA match*
HLA identical sibling
probability (n 5 32)
68 (51-83) 62 (43-79)
Well-matched URD probability
(n 5 62)
76 (64-86) 67 (55-78)
Partially matched URD probability
(n 5 15)
53 (29-77) 22 (1-61)
Transplant center†,‡
FHCRC (n 5 43) 86 (74-95) 72 (57-85)
Non-FHCRC (n 5 74) 60 (49-71) 54 (42-66)
Conditioning regimen
MA (n 5 80) 69 (58-78) 57 (46-69)
NMA/RIC (n 5 37) 72 (57-86) 69 (52-83)
Spleen status
Normal spleen 76 (60-89) 76 (60-89)
Splenomegaly 70 (56-83) 58 (43-73)
Splenectomy 67 (50-81) 58 (40-75)
MF†,‡
No MF 61 (49-73) 54 (41-67)
Transformed to MF 85 (73-93) 73 (58-86)
Treatment-related mortality*,‡
MA (95% CI; n 5 80) 31 (21-41) 40 (29-52)
NMA/RIC (95% CI; n 5 37) 14 (5-27) 18 (7-32)
CI indicates confidence interval; URD, unrelated donor; FHCRC, Fred
Hutchinson Cancer Research Center; MA, myeloablative; NMA, non-
myeloablative; RIC, reduced-intensity conditioning; MF, myelofibrosis.
*Pointwise P < .05 at 5 years.
†Log-rank P < .05.
‡Pointwise P < .05 at 1 year.
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toxicity (38%) and the primary disease (23%). One
patient died of a vascular complication.
Predictors for Survival, TRM, and Recurrence/
Progression
Table 4 summarizes univariate analysis results of
potential predictors for survival. Age, time from diag-
nosis to HCT, WBC count, platelet count, hemoglo-
bin at the time of HCT, presence of circulating blasts
at HCT, spleen status, or graft source were not signif-
icantly associated with survival. Survival was poorer for
patients receiving mismatched unrelated transplanta-
tions, although there were only 15 such patients in
this cohort. A statistically significant center effect was
associated with improved survival at 1 year, but not at
5 years after transplantation. FHCRC patients in-
cluded all the patients who underwent transplantations
at FHCRC, including those reported to the CIBMTR.
Neither aGVHD nor cGVHD correlated with the risk
of relapse (data not shown).
Eighty patients received an MA or high-intensity
conditioning regimen, and 37 patients received a
reduced-intensity or NMA conditioning regimen. In
univariate analysis, 5-year TRM was higher for
MA regimens (40% versus 18%; P\ .05; Table 4).
The 1-year and 5-year relapse rates were lower in pa-
tients receiving MA regimens, 8% versus 33% (P 5
.003) at 1 year and 9% versus 41% (P\ .001) at 5 years,
respectively. However, there was no difference in sur-
vival by regimen intensity; 5-year survival rates were
57% for patients receiving an MA regimen and 69%
for patients receiving a reduced-intensity regimen (P
. .05).
Splenomegaly and Splenectomy
Neutrophil and platelet engraftment were delayed
in patients with splenomegaly. Median time to neutro-
phil engraftment was 17 days in patients with a normal
spleen size compared to 23 days in patients with
splenomegaly (P\ .001). Median time to platelet en-
graftment was 20 days in patients with normal spleen
size and 26 days for patients with splenomegaly (P 5
.024). Patients who had undergone a splenectomy be-
foreHCThad amedian time to engraftment of 14 daysfor neutrophils and 19 days for platelets. There was no
difference in aGVHD, cGVHD, relapse, or PFS
among patients with normal spleen size, with spleno-
megaly, or those patients who had undergone a sple-
nectomy. Similarly, there was no difference in
survival (Table 4).Myelofibrosis
In 46 patients (39%), the disease had transformed
to MF before HCT (Table 4). The vast majority of
these patients were reported from the FHCRC
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versus 53 years, respectively;P5 .011) and had a longer
interval from diagnosis to transplantation (125 months
versus 75 months; P 5 .005) than those without MF.
Time from diagnosis to HCT for patients with MF
was similar for patients from the FHCRC and the
non-FHCRC groups (P 5 .22), but the FHCRC pa-
tients were more likely to have received an MA condi-
tioning regimen. Presence of MF did not affect 28-day
engraftment rates or TRM. Grades II to IV aGVHD
rates at 100 days (P 5 .028) and cGVHD rates at 1
year (P 5 .004) and 5 years (P # .001) were higher in
patients with MF. Relapse rates at 1 year (P 5 .018)
and 5 years (P 5 .015) were lower in patients with
MF (data not shown). Splenectomy had no effect on
survival of patients withMF (data not shown). Patients
with MF had a higher 1-year but not 5-year survival
post-HCT (Table 4).DISCUSSION
In this retrospective analysis, we observed that
HCT results in long-term PFS in over 45% of selected
patients with ET and PV. In particular, we found that
the probability for relapse within 1 year was low (11%)
for patients with ET, and did not increase substantially
by 5 years. Although the overall probability of relapse
was higher (25%) for patients with PV, only a small
proportion experienced relapse after the first year.
There were no relapses after 3 years for either ET or
PV. Thus, in selected patients with ET or PV, HCT
seems to be curative, and the outcome tends to be dic-
tated by transplantation-associated complications
more commonly than by resistant disease. Although
this study did not compare transplantation to conven-
tional therapies, the low rate of relapse, particularly
late after transplantation, is encouraging.
Splenomegaly is a feature typical of the myelopro-
liferative neoplasms, particularly MF; however, it has
not been clear whether splenomegaly affects outcome
of HCT. Preliminary data from the CIBMTR in
a broader population suggests that splenectomy facili-
tates engraftment, without an effect on TRM [23].
Thirty percent of our patients had undergone a sple-
nectomy at some point before transplantation, al-
though the indication for splenectomy was not
known. Our results indicate that splenomegaly is asso-
ciated with delayed neutrophil and platelet engraft-
ment, but does not seem to decrease survival and
PFS. The current study does not support routine sple-
nectomy before transplantation. Recently, posttrans-
plantation splenectomy has been reported as a way to
manage markedly delayed engraftment in 2 patients
with MF and splenomegaly [24].
Transformation to MF did not affect engraftment
or TRM, but 1-year survival was superior amongpatients whose disease had transformed toMF. In gen-
eral, patients with MF were younger at the time of
HCT, and had a significantly longer interval between
diagnosis and HCT, which may indicate more indo-
lent disease. Given the small sample size, it was not
possible to determine whetherMF itself was associated
with superior 1-year survival orwhether it was amarker
for another factor, such as younger age, or a center ef-
fect. Nonetheless, in contrast to many instances in
which disease progression is associated with inferior
outcome of HCT, progression of ET and PV to MF
does not seem to reduce the chances of survival.
The incidence of cGVHDwas observed in 48% of
our patients at 5 years post-HCT, likely reflecting the
predominance of grafts that were either peripheral
blood stem cells, from an unrelated donor, or both.
There was no correlation between GVHD and relapse
rate in our study. This finding suggests that the graft-
versus-Myeloproliferatie Disease effect may not be es-
sential for a successful transplantation outcome, al-
though this conclusion may be limited by small
numbers of patients. A report of a successful syngeneic
graft for treatment of MF supports the concept that
graft-versus-lymphoma, and therefore GVHD, are
not required [25]. Nonetheless, donor lymphocyte in-
fusion has been reported to induce clinical and molec-
ular remissions in patients who relapse after allogeneic
transplantation for PV. Therefore, at this time, the im-
munomodulatory benefit to allogeneic transplantation
in patients with ET and PV remains unclear [26].
The Seattle group initially reported a small series
of patients with ET and PV receiving allogeneic
transplants, and showed a 3-year survival of 64%
[27]. Patients with MF did better than patients who
had progressed to MDS/AML. Patients who had un-
dergone a prior splenectomy had faster neutrophil en-
graftment (15 versus 20 days; P 5 .004). An updated
study from Seattle, which included 104 patients with
MF, PV, or ET receiving allogeneic related or unre-
lated donor transplants, reported a 7-year actuarial
survival of 61% [16]. Nonrelapse mortality was 34%
at 5 years; patients who received a targeted busulfan
and cyclophosphamide regimen experienced a better
survival compared with patients treated with other
conditioning regimens. In a multivariate analysis, con-
ditioning regimen, younger age, high platelet count at
transplantation, and lower comorbidity score pre-
dicted for better survival. Twenty-five patients previ-
ously reported by the FHCRC are included in the
current analysis. In our study, neither age nor blood
counts at transplantation predicted for survival. Ap-
propriate indications for transplantation could not
be confirmed in this study, but might include develop-
ment of cytopenias, recurrent thrombosis, poor re-
sponse to standard therapy, or transformation to MF
or MDS. Strategies to reduce early toxicity (the
most common cause of death was organ toxicity)
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larly for older patients, or a targeted busulfan-based
regimen.
Robin et al. [28] analyzed the outcomes of 147
patients with MF undergoing allogeneic HCT.
Sixty-nine patients (47%) had MF secondary to PV
or ET. The 4-year overall survival was 39% (95% con-
fidence interval [CI], 30%-45%) for the entire group,
and results in patients with primary and secondary
MF were not analyzed separately. Comparisons are
difficult among the different studies with some studies
including only patients with MF (primary or second-
ary) and other studies of patients with prior leukemic
transformation.
Similar to these previous studies, our studywas lim-
ited by its retrospective nature, with transplantations
performed in a variety of centers over a prolonged
time period with different conditioning regimens and
GVHD prophylaxis regimens. Patients underwent
transplantations in 32 centers, but 1 center, the
FHCRC, contributed 43 patients. Furthermore, the
reasons for selecting HCT could not be ascertained
for all patients, although it is reasonable to assume
that the patients had at least 1 risk factor for poor out-
come with conventional therapy. At the FHCRC, pe-
ripheral blood cytopenias and evidence for
transformation toMFwere the 2most common indica-
tions for transplantation; almost one-half the patients
had transformed to MF at the time of transplantation.
Selection bias also makes it difficult to use these results
as guidance for treatment of patientswithETandPV in
general. Even though our study has a long median
follow-up of over 4 years, the population is highly se-
lectedwith a lowermedian age (49 and 53 years, respec-
tively) than the general population with ET and PV,
which is in the 7th decade [29].
Many patients with ET and PV do well with stan-
dard therapies, such as hydroxyurea, interferon, and
phlebotomy, and are not considered candidates for
HCT [10,30,31]. In addition, it is not clear how the
availability of JAK2 inhibitors, now approved by the
Food & Drug Administration, will affect the long-
term disease course and therefore modify the decision
process for or against HCT. The impact of JAK2 allele
burden on prognosis and response to therapy remains
controversial [32,33]. As JAK2 data were not available
on the majority of patients in the present study, many
of whom underwent transplantation before 2005, the
relevance of JAK2 mutation for HCT outcome could
not be assessed. Patients who had transformed to
AML were excluded from this study, but represent
a high-risk group of patients. Response to treatment
of the patients reported here was determined by the
transplantation centers, and criteria for relapse/pro-
gressionmay have differed as many patients underwent
transplantation before standard response criterions
were established [34]. Furthermore, as cytogeneticdata were often lacking, the impact of karyotype on
outcome could not be analyzed [35].
This report provides encouraging long-term out-
come results for selected patients with ET and PV re-
ceiving allogeneic HCT. Future studies will need to
determine the optimum role and timing of HCT in
the face of emerging molecular-targeted therapies for
these diseases.ACKNOWLEDGMENT
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